About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, September 5th, 2017

The QualityStocks
Daily Stock List


DanDrit Biotech USA, Inc. (DDRT)

MarketWatch and GuruFocus reported on DanDrit Biotech USA, Inc. (DDRT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DanDrit Biotech USA, Inc. is a development stage company whose devotion is to develop the world’s first vaccine against colorectal cancer. It is now engaged in development and clinical drug trials for a polytopic dendritic cell vaccine cancer immunotherapy for cancer survivors to prevent recurrence. DanDrit’s expertise in producing dendritic cells from a patient's blood is combined with conventional production methods with the aim of making new and advanced vaccines for cancer patients. DanDrit Biotech USA is planning to move its headquarters to Los Angeles, California, while keeping a presence in Denmark.

The Company has its Strategic Alliance strategy. It has built a strong pipeline of dendritic-cell-based cancer therapies, currently addressing 40 percent of all cancer-related deaths. DanDrit’s intention is to work with strategic partners to strengthen the in-house pipeline. DanDrit controls important technologies with relevance outside its core business area and these the Company says they may out-license or co-develop with appropriate partners.

The ability of dendritic cells to provoke a strong immune response is the underpinning of the vaccine therapies under development at DanDrit Biotech USA. MelCancerVac® (MCV) is a new product by the Company for colorectal cancer. MVC utilizes a vaccination treatment program in addition to the customary treatment types of chemotherapy and surgery. MCV is a dendritic cell vaccine, which could strengthen the immune response in colorectal cancer patients.

MelCancerVac® uses a patient’s own dendritic cells filled with tumor antigens from the lysate of a specifically selected melanoma cell line. MelCancerVac® has been tested in clinical trials for the treatment of two different kinds of cancer. One is colorectal cancer (CRC) and the other is non-small-cell lung cancer (NSCLC).

CRC clinical trials include Phase I at Gentofte Hospital, Denmark (Completed); Phase II at Gentofte Hospital, Denmark (Completed); and Phase II at the National Cancer Centre, Singapore (Completed). NSCLC clinical trials include Phase II at Herlev Hospital, Denmark (Completed).

DanDrit uses a patient’s own dendritic cells, taken from the blood and loaded with tumor antigens. The dendritic cells then undergo injection back into the cancer patient. There, surface expressed antigenic peptides are recognized by T lymphocytes. T lymphocytes are stimulated by the dendritic cells to proliferate and differentiate into effecter cells that target and destroy tumor cells specifically.

The Company’s therapeutic cancer vaccine is used either as separate treatment or complementary to other kinds of treatment, including surgery, chemotherapy, and radiotherapy. DanDrit Biotech USA has also developed methods to produce tolerance-promoting dendritic cells for use in the treatment of autoimmune disease.

In June of this year, DanDrit Biotech USA announced that on June 6, 2017, Mr. Rene Sindlev and Mr. Torben Bjørn Christensen joined the Company’s Board of Directors as part of a new strategy to expand DanDrit's emphasis beyond its continuing clinical drug trials to develop new therapeutic programs to treat cancer and other serious diseases.

Mr. Sindlev and Mr. Christensen have been instrumental in raising the additional capital essential to implement DanDrit Biotech USA's new strategy. Also, regarding their appointment to the Board of Directors, DanDrit is recruiting leading scientific talent to start pre-clinical studies for the Company’s new biotechnology initiatives and to strengthen its Intellectual Property (IP) positions.

DanDrit Biotech USA, Inc. (DDRT), closed Tuesday's trading session at $2.00, even for the day. The average volume for the last 60 days is 577 and the stock's 52-week low/high is $0.70/$3.00.

Weyland Tech, Inc. (WEYL)

DreamTeamNetwork, Wall Street Mover, and OTCJournal reported earlier on Weyland Tech, Inc. (WEYL), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Weyland Tech, Inc. is a provider of mobile business applications. The focus of the Company’s CreateApp platform is on the Asia markets. Weyland Tech presently offers the CreateApp platform directly in Singapore, India (Jaipur), and the U.S.A. and Canada. The Company’s CreateApp platform is provided in 12 languages. The "CreateApp" platform enables SMBs (Small-Medium-Sized Businesses) to create a mobile application without the requirement of technical knowledge and background. Weyland Tech is headquartered in Hong Kong.

Weyland Tech currently offers a DIY (Do-it-Yourself) App builder through a 'white label' platform. It offers this through strategic partnerships in the EU (minus Russia, Turkey, Armenia, Azerbaijan); Malaysia; Hong Kong/South China; Indonesia; and North/Central/South America. It will offer this in Korea through IAM, Inc.

Weyland Tech signed a Master Service Agreement (MSA) with Orient Asia Pacific Limited (OAP). This is for the Indonesia market. OAP is a software and digital technology consulting enterprise. In September 2016, Weyland Tech announced that it signed a strategic licensing agreement with BGT Corporation Public Company Limited (BGT), for the Thailand market.

Weyland Tech's partner in Indonesia, OAP, recently signed an agreement to provide a stored-value 'top-up' application targeted at the 120 million adults living without access to traditional banking facilities. The design of the application is to be offered through major telecommunications providers in Indonesia. OAP has started a pilot program to 20 communities in Indonesia. OAP will offer the community application to the other 500,000 communities across Indonesia upon success of the pilot.

Weyland Tech has entered into an advisory agreement with TMC Prime Pte. Ltd (TMC). This agreement is to secure strategic investments by Southeast Asian technology companies and high-net-worth individuals with experience investing in technology firms. TMC will commit to fund up to $10 million USD over a period of one year by way of direct investments into Weyland Tech. The intention of these funds is to be used for expansion and pilot programs aimed at exploiting the enormous potential in the fast expanding Indonesian mobile commerce (m-commerce) market.

Regarding strategic partnerships, Weyland Tech has partnered with and is finalizing partnerships with major payment gateways in the ASEAN region and the incumbent telecoms that provide payment solutions to the different locales in nations like Indonesia. Weyland Tech has a strategic partnership with DPEX. This is one of the ASEAN regions incumbent logistics players with infrastructure throughout every country in the region. This enables Weyland Tech to provide delivery for e/m-commerce customers.

Weyland Tech’s exclusive Eurozone partner, Augicom S.A., has entered into a partnership with Orange Pro. As part of the agreement, Weyland Tech's CreateApp will be made available to Orange Pro clients through the "la Carte Pro" program or 'Pro Card' in English. The "Pro Card" program of Orange is a loyalty program for independent professionals and SMBs. Augicom is an active provider of voice/data telecommunication minutes. It has major partnerships with major European carriers.

Weyland Tech, Inc. (WEYL), closed Tuesday's trading session at $4.44, up 3.26%, on 3,365 volume with 13 trades. The average volume for the last 60 days is 5,075 and the stock's 52-week low/high is $2.70/$6.95.

Citius Pharmaceuticals, Inc. (CTXR)

MicroCapDaily, Stock Commander, Penny Stock Prodigy, DSR News, PHUB News, Damn Good Penny Picks, Penny Picks, OTCtipReporter, PennyStockScholar, Profitable Trader Authority, OTCMagic, Penny Stock Newsletter, and PREPUMP STOCKS reported previously on Citius Pharmaceuticals, Inc. (CTXR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products. The Company’s concentration is on anti-infectives, cancer care, and innovative prescription products utilizing unique, patented, or proprietary formulations of earlier approved active pharmaceutical ingredients. Citius Pharmaceuticals is headquartered in Cranford, New Jersey.

The Company is now advancing two proprietary product candidates: the Mino-Lok™ product and a hydrocortisone-lidocaine formulation. The Mino-Lok™ product is advancing to Phase 3 clinical studies. The Mino-Lok™ product is an antibiotic lock solution. It is used to treat patients with catheter-related bloodstream infections (CRBSIs). Mino-Lok™ is under investigation and not approved for commercial use.

Citius Pharmaceuticals is developing a proprietary topical formulation of hydrocortisone (3%) and lidocaine (5%) to provide anti-inflammatory and anesthetic relief to persons suffering from Grade I and II hemorrhoids. The Company has achieved positive results from a Phase 2a study for hydrocortisone-lidocaine formulation for Grade I and II hemorrhoids.

Citius Pharmaceuticals has commenced the pivotal Phase 3 clinical trial Mino-Lok™. This is the above-mentioned antibiotic lock solution used to salvage infected central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs). Mino-Lok™ is undergoing development as an adjunctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI). Mino-Lok™ together with suitable systemic antibiotic(s), is used to preserve central venous access and to avoid the complications and morbidities associated with catheter removal and reinsertion.

The Company has obtained top line data from a survey of 31 physicians clearly showing a need for catheter salvage in patients with indwelling central venous lines, especially when the catheter is a tunneled or an implanted port. Nineteen Infectious Disease experts and 12 Intensivists surveyed all agreed that salvage would be preferable to catheter exchange, fearing that catheter misplacements, blood clots, or vessel punctures can potentially occur during reinsertion. Most were also concerned that viable venous access may not be available. The survey was conducted by a third party in January of this year.

In March 2017, Citius Pharmaceuticals announced that it concluded negotiations to add South America to its global license for Mino-Lok™. South America was the only territory that was not included in the original sub-license between Novel Anti-Infective Technologies, LLC, an affiliate of MD Anderson Cancer Center (MDACC), and Leonard-Meron Biosciences, Inc. (LMB), a wholly-owned subsidiary of Citius Pharmaceuticals.

Citius Pharmaceuticals, Inc. (CTXR), closed Tuesday's trading session at $3.70, down 1.33%, on 29,591 volume. The average volume for the last 52 days is 14,132 and the stock's 52-week low/high is $2.55/$14.85.

Blox, Inc. (BLXX)

OTC Markets Group, SmallCapVoice, and PennyStocks24 reported earlier on Blox, Inc. (BLXX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Blox, Inc.’s vision is to pioneer the development of mining projects through applying green innovation to traditional mining methods and combining renewable energy and technology into the process. Its plan is to become an international leader in the production of “green minerals”. A key component of Blox’s mandate is to implement clean energy into the mining process. This is to effectively “green” the mining process and minimize its environmental impact via lower hydrocarbon emissions.

Blox plans on building a portfolio of gold and other minerals and producing them in a socially and environmentally friendly way. Blox Minerals is a wholly-owned subsidiary of Blox, Inc. Blox is headquartered in Vancouver, British Columbia.

Box defines “green minerals” as minerals produced employing technologies, best practices, and mine processes implemented to reduce the environmental impacts associated with the extraction and processing of metals and minerals. The Company’s plan is to use renewable energy and technology in the production of green minerals with the goal of turning expensive costs into profits through using renewable energy plants to power its different projects.

Regarding technology, the foundation of this division of the Company is rooted in the acquisition of the rights to proprietary Enterprise Resource Planning (ERP) software called “Abacus”. As Blox grows it will be able to manage its various operating and development projects with its own software system.

Blox’s key concession holdings are in Ghana and Guinea, West Africa. Its projects include Pramkese, Osenase, Asamankese, and Mansounia. The Pramkese concession is about 10km southeast of the District Capital of Kade in the Eastern Region of Ghana. The Osenase concession is roughly 90 km north-northwest of Accra in the Birim Central Municipal Assembly, Eastern Region, Ghana.

The Asamankese concession is approximately 90 km north-northwest of Accra in the Birim South and West Akim District Assemblies, East of Akim Oda, Eastern Region. The Birim region Kibi-Winneba Belt has produced significant alluvial gold and diamonds since 1919. Much of the Kibi-Winneba belt is underdeveloped and underexplored.

The Mansounia Exploration Licence is centered on Latitude 10º 23’ N and Longitude 9º 47’ W in the Kouroussa Prefecture, Kankan Region, in Guinea, West Africa. It encompasses a surface area of 145 square kms. At Mansounia, significantly fresh rock mineralization has been intersected and as of July 2016, remains unexplored. Mansounia is a priority development asset for Blox.

Geological reconnaissance over the central and southern Mansounia concession target areas was completed during Q1 of 2017. Geological mapping of regolith identified wide-ranging lateritic cover with minor outcrop containing in-situ veining. Moreover, 19 rock chip/grab samples were collected around minor local excavations in lateritic cover. Of the 19 samples, 9 samples surpassed geological background values for the area of >=20ppb, representing 47 percent of the samples taken.

In July, Blox announced the completion of field activities associated with a detailed Environmental and Social Impact Assessment (ESIA). This concludes a major stage toward obtaining a Mining License for the Mansounia Gold Project. The ESIA is the start of an ongoing process of involvement on all social and environmental fronts.

Blox, Inc. (BLXX), closed Tuesday's trading session at $0.22, up 10.00%, on 148,625 volume with 8 trades. The average volume for the last 60 days is 52,348 and the stock's 52-week low/high is $0.013/$0.35.

Kenadyr Mining (Holdings) Corp. (KNDYF)

Awesome Penny Stocks, Morningstar, MarketWatch, and InvestorsHub reported on Kenadyr Mining (Holdings) Corp. (KNDYF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Kenadyr Mining (Holdings) Corp. engages in the exploration of the historic Borubai Gold Project in the Kyrgyz Republic in Central Asia. The Borubai Project has had 81,800 meters of historic drilling. Kenadyr has significant in country experience and worldwide mining experience. This experience ranges from discovery and exploration to production. Kenadyr Mining’s shares trade on the OTC Markets Group’s OTCQB. The Company has its headquarters in Vancouver, British Columbia.

Kenadyr Mining holds a 100 percent interest in Borubai Exploration License (164 km2). The license is in a foothill area at low altitudes above sea level providing easy year-round operations. The area has well developed infrastructure with two lines of high-voltage power grid as well as access roads to all prospects.

Additional high-grade gold targets are present throughout the Borubai Exploration License. The whole license has been subject to extensive geochemical and geophysical surveys, with follow up trenching and drilling on only a few of the identified anomalies. Two formerly drilled on-surface prospects (Suhaia Schel (SS) and Karacha) are immediate additional drill targets.

The Borubai Project shares connecting mineralization with a producing high-grade gold mine. Borubai encircles Zijin’s Taldybulak Levoberejnyi Mine (TBL Mine). This is a newly built and producing mine containing 3.2Moz in reserves and resources at a grade of 7.2 g/t.

Kenadyr Mining has a complete database from 410 drill holes. This includes drilling at the TBL Deposit. On the Borubai License, 139 holes (81,000m) were drilled next to the TBL Mine.

This past June, Kenadyr Mining announced that the second drill hole of the 2017 season, collared at the East Zone on the Company’s Borubai License, Kyrgyz Republic, intersected 50 meters at 8.15 g/t Au, from a downhole depth of 151 m to 201m.

Dr. Alexander Becker, Chief Executive Officer of Kenadyr Mining, stated, "These results from our second 2017 drill hole at Borubai have again exceeded our expectations. This latest drill hole, located on Kenadyr's license and drilled at the East Zone, demonstrates that highly significant gold mineralization also continues strongly to the East of the TBL Deposit, onto Kenadyr's License. Technical staff believe, based on the strength of the mineralization encountered in our first two 2017 drill holes that the mineralization being mined at the adjacent TBL Mine continues strongly in two directions along strike onto Kenadyr's Borubai License. As well, based on the geometry of the TBL deposit, the Corporation is confident that these intersections are approximate 'true widths'."

Kenadyr Mining (Holdings) Corp. (KNDYF), closed Tuesday's trading session at $0.275, even for the day, on 1,500 volume with 1 trade. The average volume for the last 60 days is 15,320 and the stock's 52-week low/high is $0.21/$1.45.


The QualityStocks
Company Corner


ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.77, off by 4.94%, on 123,841 volume with 106 trades. The stock’s average daily volume over the past 60 days is 45,316 and its 52-week low/high is $0.315/$2.75.

WallStreet Research™ (WSR), a top-ranked independent research firm with a history spanning over three decades, today announced that the firm has updated Corporate Profile coverage on ChineseInvestors.com Inc. (OTCQB: CIIX).  WallStreet Research™ is ranked Number One on the Google, Yahoo, and Bing search engines in both small and microcap research with a global following.  An updated analyst Corporate Profile Report, together with additional information about WallStreet Research, is available at the http://www.WallStreetResearch.org website. The WSR Corporate Profile highlights the Company's recent accomplishments and growth plans for 2017 and beyond.  

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

WallStreet Research™ Announces Availability of Updated Corporate Profile Coverage on ChineseInvestors.com Inc. (OTCQB: CIIX)

ChineseInvestors.com, Inc. Announces Plans to Launch the First Chinese Daily Video News Broadcast from the NYSE Covering Cryptocurrency and Blockchain Technology

NetworkNewsWire Announces Publication Discussing the Monumental Impact of Bitcoin on the Cannabis Sector

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.022109, off by 5.52%, on 10,284,979 volume with 185 trades. The stock’s average daily volume over the past 60 days is 1,661,633, and its 52-week low/high is $0.0077/$0.04.

Global Payout, Inc. (GOHE) was pleased to announce today that it is currently in the process of completing its financial audit in preparation for the filing of the Company's Form 10-K which the Company anticipates should be completed for filing with the Securities and Exchange Commission ("SEC") within the next 60 days.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout, Inc. Begins Company Audit with Intent of Filing Form 10-K and Becoming Fully Reporting Within 60 Days

NetworkNewsWire Announces Publication Highlighting Innovative Public FINTECH Companies

NetworkNewsWire Releases Exclusive Interview with Global Payout, Inc. (GOHE)

Algae Dynamics Corp. (ADYNF)

The QualityStocks Daily Newsletter would like to spotlight Algae Dynamics Corp. (ADYNF). Today, Algae Dynamics Corp. closed trading at $0.13, up 30.00%, on 54,656 volume with 5 trades. The stock’s average daily volume over the past 60 days is 11,236 and its 52-week low/high is $0.0001/$0.62.

Algae Dynamics Corp. (ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.

The original core of the company's product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

Although the company is publicly traded in the U.S., business is conducted in Canada with no exposure to U.S. federal regulation involving cannabis. The Canadian cannabis oil extraction marketplace is projected to grow from C$1 million in 2015 to C$1.7 billion in 2020, which is more than a 1,000-fold increase. With the Government of Canada indicating a target date for full legalization on or before July 2018, numerous opportunities for sales in extracts and oils will open up very soon.

Using Colorado as a comparable example, a study performed by Mackie Research Capital found that 45% of dried marijuana users in the state would eventually convert to marijuana extracts and oils. This is because most consumers taking cannabis for medical purposes are increasingly looking for delivery systems that do not involve smoking marijuana. The market's attractiveness can be further realized when considering that the Canada's licensed producer marketplace is far less competitive with 45 current licensed producers for the whole country vs. 624 licensed cultivators in Colorado.

Collaborating with prominent Canadian universities is a core part of the Algae Dynamics' plan to bolster cannabis extraction expertise, develop premium products and add to its portfolio of intellectual property. Through its agreements with the University of Waterloo and the University of Western Ontario, the company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. Algae Dynamics also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has nearly a century of beneficial experience spanning from management and process experience to successful fund raising and commercialization.

As part of its key objective to be the #1 research Canadian cannabis oil research-driven product formulator, the company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. Individuals who support the company's initiatives include Dr. Jonathan Blay PhD, FRSB, FIBMS, Csci, CBiol, who performs research and product development on cannabis oil and its constituents in the context of colorectum, pancreas, breast and prostate cancers; and Dr. Steven Laviolette, BSc, PhD, who performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

With such a strong foundation laid in the areas being pursued, Algae Dynamics is well positioned to execute on its carefully developed business plan to fast-track to revenue growth while having a longer-term strategy to build a sustainable enterprise-building opportunity in a rapidly expanding market. Disclaimer

Algae Dynamics Corp. Blog

Algae Dynamics Corp. News:

Algae Dynamics Corp Enters Into a Letter of Intent with Bonify to Produce Unique Cannabis Oil Products; Accelerates Go-to-Market Strategy

NetworkNewsWire Releases Exclusive Audio Interview with Algae Dynamics Corp. (ADYNF)

Algae Dynamics Corp. (ADYNF) Engages NetworkNewsWire for Corporate Communications Solutions

HighCom Global Security, Inc. (HCGS)

The QualityStocks Daily Newsletter would like to spotlight HighCom Global Security, Inc. (HCGS). Today, HighCom Global Security, Inc. closed trading at $0.023, up 31.43%, on 30,000 volume with 2 trade. The stock’s average daily volume over the past 60 days is 8,207 and its 52-week low/high is $0.0051/$0.10.

HighCom Global Security, Inc. (HCGS) is a manufacturer and distributor of protective products for military and law enforcement personnel. The Corporation operates under two segments, BlastGard Defense Group and Highcom Security.

BlastGard is a blast mitigation specialist with proprietary material proven to effectively mitigate blasts and suppress fires resulting from explosions. The company's patented BlastWrap® technology acts as a "virtual tent" to effectively mitigate blast effects and suppress post-blast fires. This unique technology works by triggering physical and chemical processes to dissipate blast energy, thereby reducing the aftermath of acoustic and shock waves, peak overpressure, reflected peak overpressure, impulse and afterburn. The remaining, significantly reduced energy is transmitted at a slower, more sustainable level. Notably, BlastWrap does not dispense chemical extinguishants; uses neither alarms, sensors, nor an activation system; and is nontoxic and ecologically friendly.

Similarly, the company's BlastGard MTR trash receptacles dramatically reduce lethal threats posed by the detonation of an improvised explosive device (IED). Equipped with Triple Wall Technology, BlastGard MTR mitigates primary fragments, secondary fragments, mechanical effects (shock/blast pressure) and thermal effects (contact and radiation burn) from the fireball, after-burn and resultant post-blast fires.

BlastGard's primary market focus lies on providing blast effects mitigation solutions for customers operating in the commercial sector, military, law enforcement and government agencies. With a vision of being recognized as the leading provider of environmentally responsible solutions to protect lives and structures from the hazards associated with fire and explosions, the company is capable of addressing a wide array of industry applications spanning from fire suppression for naval vessels and merchant ships to protection of buildings against vehicle bombs.

This vision is supported by the ban of Halon extinguishing agents, as outlined in the Montreal protocol, which effectively establishes BlastWrap® as the only blast and fire suppression means available for most applications, including adaptation for underwater use.

The company's position at the head of the blast suppression market has helped BlastGard attain a number of government awards, including designation of its BlastWrap® product as a Qualified Anti-Terrorism Technology and placement on the "Approved Products List for Homeland Security." This designation was extended in early 2017, meaning that BlastWrap® is approved for use by the Department of Homeland Security under the SAFETY Act until November 2021.

HighCom Security, develops, tests, manufactures and distributes body armor and personal protective equipment, including more than two dozen NIJ (National Institute of Justice) compliant hard and soft armor products. Highcom Security has a 20-year history of producing quality armor with no operational failures and no recalls of its American made products.

Highcom Security was founded in 1997 and has produced close to 1 million pieces of armor for the Global community. The company is ISO 9001:2008 certified and the first company in the world to be BA 9000:2012 certified compliant.

For the past decade, Highcom Security has also been able to offer some of the largest armor manufacturers with private label/OEM hard armor solutions for end use by military and law enforcement agencies globally, a market reach obtained because of the company's reputation for innovative technology, exceptional customer service and superior quality performance. Disclaimer

HighCom Global Security, Inc. Blog

HighCom Global Security, Inc. News:

HighCom Global Security Issues Update on Product Technology Advances

HighCom Global Security Introduces New CEO and Board of Directors as Part of Globally Focused Restructuring Plan

BlastGard International, Inc. Announces Name and Symbol Change to HighCom Global Security, Inc. (HCGS), Rebranding Initiative to Reflect Expanded Growth Strategy

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.2335, up 6.62%, on 241,577 volume with 133 trades. The stock’s average daily volume over the past 60 days is 264,256, and its 52-week low/high is $0.062/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Announces Appointment of Creative Capital Media

InMed Announces Publication in European Journal of Pain

InMed Pharma Advances Cannabinoid EB Therapy -- CFN Media


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(TBACQ) +1,045.83%


The Street
(INSM) +119.61%


(XOMA) +44.19%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251